CureVac N.V. $CVAC Shares Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank AG increased its stake in CureVac N.V. by 35.9%, owning 230,813 shares valued at approximately $639,000, according to its recent SEC filing.
• Several institutional investors have recently adjusted their stakes in CureVac, contributing to a total institutional ownership of 17.26%.
• Analysts have issued mixed ratings for CureVac, with an average target price of $6.83 and most firms rating the stock as a "hold".

Deutsche Bank AG increased its holdings in shares of CureVac N.V. (NASDAQ:CVAC - Free Report) by 35.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 230,813 shares of the company's stock after buying an additional 60,941 shares during the period. Deutsche Bank AG owned about 0.10% of CureVac worth $639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Greenleaf Trust acquired a new position in CureVac during the first quarter worth $31,000. Two Sigma Advisers LP purchased a new stake in shares of CureVac during the fourth quarter worth about $48,000. Jump Financial LLC acquired a new stake in CureVac in the 4th quarter worth about $55,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of CureVac in the fourth quarter worth approximately $66,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in CureVac by 14.3% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,125 shares of the company's stock worth $81,000 after acquiring an additional 3,648 shares during the last quarter. Institutional investors and hedge funds own 17.26% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Citizens Jmp lowered CureVac from a "strong-buy" rating to a "hold" rating in a research note on Thursday, June 12th. Citigroup lowered shares of CureVac to a "market perform" rating in a report on Thursday, June 12th. Jefferies Financial Group reissued a "hold" rating and issued a $5.00 price target (down previously from $7.00) on shares of CureVac in a research note on Friday, June 13th. UBS Group cut CureVac from a "strong-buy" rating to a "neutral" rating and decreased their price objective for the company from $12.00 to $5.50 in a report on Thursday, June 26th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $10.00 price target on shares of CureVac in a research note on Wednesday, May 28th. One analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, CureVac presently has a consensus rating of "Hold" and a consensus price target of $6.83.

CureVac Stock Performance

CVAC remained flat at $5.37 during mid-day trading on Monday. The company had a trading volume of 321,215 shares, compared to its average volume of 636,357. The firm's fifty day moving average price is $5.43 and its two-hundred day moving average price is $4.23. CureVac N.V. has a 1 year low of $2.37 and a 1 year high of $5.72. The company has a market cap of $1.20 billion, a P/E ratio of 5.59 and a beta of 2.53. The company has a current ratio of 6.17, a quick ratio of 6.16 and a debt-to-equity ratio of 0.05.

CureVac (NASDAQ:CVAC - Get Free Report) last released its earnings results on Thursday, August 21st. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.15). The firm had revenue of $1.41 million during the quarter, compared to analyst estimates of $4.27 million. CureVac had a net margin of 38.21% and a return on equity of 29.57%. As a group, research analysts anticipate that CureVac N.V. will post 0.72 earnings per share for the current year.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.